Back
Sabine Royalty Trust 10K Form
Buy
51
SBR
Sabine Royalty Trust
Last Price:
63.00
Seasonality Move:
0%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-07 | 10Q | SBR/Sabine Royalty Trust Quarterly |
| 2023-08-04 | 10Q | SBR/Sabine Royalty Trust Quarterly |
| 2023-05-08 | 10Q | SBR/Sabine Royalty Trust Quarterly |
| 2022-11-10 | 10Q | SBR/Sabine Royalty Trust Quarterly |
| 2022-08-11 | 10Q | SBR/Sabine Royalty Trust Quarterly |
| 2022-05-12 | 10Q | SBR/Sabine Royalty Trust Quarterly |
Receive SBR News And Ratings
See the #1 stock for the next 7 days that we like better than SBR
SBR Financial Statistics
Sales & Book Value
| Annual Sales: | $93.01M |
|---|---|
| Cash Flow: | $61.06M |
| Price / Cash Flow: | 4.54 |
| Annual Sales: | $0.58 |
| Price / Book: | 107.87 |
Profitability
| EPS (TTM): | 6.49000 |
|---|---|
| Net Income (TTM): | $94.62M |
| Gross Margin: | $60.79M |
| Return on Equity: | 1153.29% |
| Return on Assets: | 1003.88% |
Sabine Royalty Trust Earnings Forecast
Key Sabine Royalty Trust Financial Ratios
- The Gross Profit Margin over the past 3 years for SBR is 100.00%.
- The Selling, General & Administrative Expenses for SBR have been equal to 3.83% of Gross Profit Margin.
- The Net Earning history of SBR is 97.03% of Total Revenues.
- Per Share Earnings over the last 40 years have been positive in 20 years.
Sabine Royalty Trust Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYSE |
|---|---|
| Industry: | Oil, Gas & Consumable Fuels |
| Sector: | Energy |
| Current Symbol: | SBR |
| CUSIP: | 785688 |
| Website: | sbr-sabine.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 39.04 |
| Quick Ratio: | 39.04 |
Price-to-Earnings
| Trailing P/E Ratio: | 10.19 |
|---|---|
| Forward P/E Ratio: | 0 |
SBR Technical Analysis vs Fundamental Analysis
Buy
51
Sabine Royalty Trust (SBR)
is a Buy
Is Sabine Royalty Trust a Buy or a Sell?
-
Sabine Royalty Trust stock is rated a Buy
The current Sabine Royalty Trust [SBR] share price is $63.07. The Score for SBR is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.